guanylate cyclase activator 2AGenealiases: GCAP-I · GUCA2 · STARA
Q-omics provides the consensus-scored GUCA2A profile across patient tissues and cancer cell-line models. GUCA2A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GUCA2A is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, GUCA2A RNA expression shows 10,712 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, COAD, and TGCT as cancer lineages where GUCA2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCA2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCA2A survival associations across molecular data types. GUCA2A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCA2A RNA expression–survival associations across cancer types. High GUCA2A expression shows unfavorable associations in UCEC, HNSC, DLBC, THYM, SKCM and UVM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for GUCA2A RNA expression.
This table summarizes GUCA2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GUCA2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCA2A shows lower tumor expression in COAD, LUSC, LUAD and READ and higher tumor expression in CHOL and BLCA. The COAD box plot shows higher GUCA2A RNA expression in normal versus tumor tissue (log2 FC = −5.854, t-test p < 0.001).
This table shows molecular features associated with GUCA2A in patient tissues and cancer cell lines. In patient samples, GUCA2A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GUCA2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
